LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Assayed Quality Control Suitable for Most Immunoassay Analyzers

By LabMedica International staff writers
Posted on 20 Aug 2013
An assayed Quality Control (QC) is suitable for use with most immunoassay analyzers. Assigned values are provided for nine immunoassay parameters, and it is the only multianalyte immunoassay QC in the market which contains clinically relevant levels of Vitamin D.

Randox’s (Crumlin, United Kingdom) Acusera Immunoassay Speciality 1 control will provide laboratories with the means to monitor the precision of their testing methods and is an aid to ensuring quality patient results on an ongoing basis.

Image: Randox Acusera compressed vials (Photo courtesy of Randox).
Image: Randox Acusera compressed vials (Photo courtesy of Randox).

Randox controls are true third party controls, manufactured independently using 100% human serum, which has been highly screened to ensure quality. This minimizes antibody cross reactivity, reducing the possibility of lot to lot variations when changing control batches thereby saving laboratories time and money.

Lyophilized for enhanced stability, when reconstituted the control will remain stable for up to 5 days at 2–8 °C or 4 weeks at -20 °C.

Randox announced that the US Food and Drug Administration (FDA; Silver Spring, MD, USA) has approved the company’s Acusera Immunoassay Specialty 1 control for use in US laboratories. Randox’s global QC manager Steven Jordan said, “We are delighted to receive FDA clearance. It will allow our US customers to benefit from improved accuracy in patient testing, whilst reducing the laboratory’s need to run multiple control tests.”

Related Links:

Randox
US Food and Drug Administration



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Urinalysis Solution
UN-9000
New
Chromogenic Culture System
InTray™ COLOREX™ ECC

Latest Immunology News

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
20 Aug 2013  |   Immunology

Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
20 Aug 2013  |   Immunology

Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
20 Aug 2013  |   Immunology



INTEGRA BIOSCIENCES AG